Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study.
Consoli A, Çabal Berthoumieu S, Raffin M, Thuilleaux D, Poitou C, Coupaye M, Pinto G, Lebbah S, Zahr N, Tauber M, Cohen D, Bonnot O.
Transl Psychiatry. 2019 Nov 4;9(1):274. doi: 10.1038/s41398-019-0597-0.

Cost-Effectiveness Analysis of Topiramate versus Phenobarbital in the Treatment of Children with Febrile Seizure.
Nemati H, Talebianpour H, Lotfi F, Sepehri NZ, Keshavarz K.
Iran J Child Neurol. 2019 Fall;13(4):109-120.

Topiramate add-on therapy for drug-resistant focal epilepsy.
Bresnahan R, Hounsome J, Jette N, Hutton JL, Marson AG.
Cochrane Database Syst Rev. 2019 Oct 23;10:CD001417. doi: 10.1002/14651858.CD001417.pub4.

FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
Rothrock JF, Adams AM, Lipton RB, Silberstein SD, Jo E, Zhao X, Blumenfeld AM; FORWARD Study investigative group.
Headache. 2019 Sep 26. doi: 10.1111/head.13653.

The Effects of folic acid and topiramate on peripheral nerve regeneration.
Sağır D, Kuruoğlu E, Onger ME, Yarar E.
Biotech Histochem. 2019 Aug 19:1-8. doi: 10.1080/10520295.2019.1637022.

Topiramate plus Cooling for Hypoxic-Ischemic Encephalopathy: A Randomized, Controlled, Multicenter, Double-Blinded Trial.
Nuñez-Ramiro A, Benavente-Fernández I, Valverde E, Cordeiro M, Blanco D, Boix H, Cabañas F, Chaffanel M, Fernández-Colomer B, Fernández-Lorenzo JR, Kuligowski J, Loureiro B, Moral-Pumarega MT, Pavón A, Sánchez-Illana A, Tofé I, Hervás D, García-Robles A, Parra-Llorca A, Cernada M, Martinez-Rodilla J, Lorente-Pozo S, Llorens R, Marqués R, Vento M; on behalf of the Hypotop Study Group.
Neonatology. 2019;116(1):76-84. doi: 10.1159/000499084.

Topiramate: Comprehensive profile.
Khalil NY, AlRabiah HK, Al Rashoud SS, Bari A, Wani TA.
Profiles Drug Subst Excip Relat Methodol. 2019;44:333-378. doi: 10.1016/bs.podrm.2018.11.005.

Impulsiveness as a predictor of topiramate response for cocaine use disorder.
Blevins D, Wang XQ, Sharma S, Ait-Daoud N.
Am J Addict. 2019 Feb;28(2):71-76. doi: 10.1111/ajad.12858.

Comparison of the Efficacy of Amitriptyline and Topiramate in Prophylaxis of Cyclic Vomiting Syndrome.
Bagherian Z, Yaghini O, Saneian H, Badihian S.
Iran J Child Neurol. 2019 Winter;13(1):37-44.

Topiramate and Metformin Are Effective Add-On Treatments in Controlling Antipsychotic-Induced Weight Gain: A Systematic Review and Network Meta-Analysis.
Zhuo C, Xu Y, Liu S, Li J, Zheng Q, Gao X, Li S, Jing R, Song X, Yue W, Zhou C, Upthegrove R.
Front Pharmacol. 2018 Nov 28;9:1393. doi: 10.3389/fphar.2018.01393.

Topiramate for the Treatment of Dually Dependent on Opiates and Cocaine: A Single-center Placebo-controlled Trial.
Pirnia B, Soleimani AA, Malekanmehr P, Pirnia K, Zahiroddin A.
Iran J Public Health. 2018 Sep;47(9):1345-1353.

Topiramate Treatment of Alcohol Use Disorder in Clinical Practice.
Jefee-Bahloul H, Jorandby L, Arias AJ.
J Addict Med. 2019 Jan/Feb;13(1):23-27. doi: 10.1097/ADM.0000000000000444.


Safety

Macular neurosensory retinal detachment associated with topiramate use.
Muñoz Morales A, Sánchez-Vicente JL, Franco Ruedas C, de Las Morenas Iglesias J, Espiñeira Periñán MÁ, López-Herrero F.
Arch Soc Esp Oftalmol. 2019 Oct 11. pii: S0365-6691(19)30238-2. doi: 10.1016/j.oftal.2019.07.014.

Physical Dependence in Patient With Chronic Low Back Pain Treated With Topiramate: A Case Report.
Bratton RH, Ward SA.
A A Pract. 2019 Aug 19. doi: 10.1213/XAA.0000000000001074.

High Incidence of Renal Stones in Severely Disabled Children with Epilepsy Treated with Topiramate.
Ishikawa N, Tani H, Kobayashi Y, Kato A, Kobayashi M.
Neuropediatrics. 2019 Jun;50(3):160-163. doi: 10.1055/s-0038-1676287.

Acute narrow-angle glaucoma induced by topiramate with acute myopia and macular striae: A case report.
Sierra-Rodríguez MA, Rodríguez-Vicente L, Chavarri-García JJ, Del Río-Mayor JL.
Arch Soc Esp Oftalmol. 2019 Mar;94(3):130-133. doi: 10.1016/j.oftal.2018.11.005.

Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampanel.
Hansen CC, Ljung H, Brodtkorb E, Reimers A.
Behav Neurol. 2018 Nov 15;2018:2064027. doi: 10.1155/2018/2064027

Topiramate (2, 3, 4, 5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate) is an antiepileptic, gamma-aminobutyric acid antagonist with the ability to inhibit compulsive desire for food and engaging behavior.

It is also used to prevent migraine and in alcohol and drug dependence.

Bipolar disorder or manic-depressive psychosis, can increase the risk of obesity and weight gain. Topiramate and sibutramine may have comparable effects of weight loss in overweight or obese bipolar patients (1).

In patients with schizophrenia, weight gain associated with olanzapine is a major concern. In this study topiramate may prevent olanzapine-induced weight gain and adverse metabolic effects (2).

In elderly people with epilepsy there is a problem of difficulty in ingesting antiepileptic tablets that should not be cut, crushed or chewed. Topiramate can be mixed with soft foods (3).

In pediatrics, an effective dosage regime has been established for the approval by the U.S. Food and Drug Administration of topiramate for initial monotherapy in pediatric patients aged 2-9 years. This study indicated an effective dosing regime for the approval by the U.S. Food and Drug Administration of the topiramate concerning initial monotherapy in pediatric patients aged between 2 and 9 years with diagnosis of partial onset seizures and primary generalized tonic-clonic seizures with a pharmacometric bridge approach (4).

Topiramate studies

Molecular Formula: C₁₂H₂₁NO₈S

Molecular Weight: 339.36 g/mol

CAS: 97240-79-4

EC Number: 619-263-3

NSC Number: 759251

UNII: 0H73WJJ391

DSSTox Substance ID: DTXSID8023688

MDL number MFCD00865320

PubChem Substance ID 24724627

Sinonimi:

• (-)-BETA-D-FRUCTOPYRANOS-[(3AS,5AR,8AR,8BS)-2,2,7,7-TETRAMETHYLTETRAHYDRO-3AH-BIS[1,3]DIOXOLO[4,5-B:4',5'-D]PYRAN-3A-YL]METHYL SULFAMATE
• 2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate
• Topamax
• Topimax
• Epitomax
• Topiramato
• Topamax Sprinkle
• Tipiramato
• Tipiramate
• RWJ 17021
• Topiramatum
• McN 4853

References________________________________________________

(1) A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders.  McElroy SL, Frye MA, Altshuler LL, Suppes T, Hellemann G, Black D, Mintz J, Kupka R, Nolen W, Leverich GS, Denicoff KD, Post RM, Keck PE Jr.  Bipolar Disord. 2007 Jun;9(4):426-34.

(2) Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.  Narula PK, Rehan HS, Unni KE, Gupta N. Schizophr Res. 2010 May;118(1-3):218-23. doi: 10.1016/j.schres.2010.02.001.

(3) Advances with extended and controlled release formulations of antiepileptics in the elderly.  Banach M, Miziak B, Borowicz-Reutt KK, Czuczwar SJ.  Expert Opin Pharmacother. 2019 Feb;20(3):333-341. doi: 10.1080/14656566.2018.1549543.

(4) Pharmacometric Bridging Approach for U.S. Food and Drug Administration Approval and Identification of Topiramate Dosing Regimen for Pediatric Patients 2-9 Years of Age With Epilepsy.  Marathe A, Liu C, Kapcala LP, Hershkowitz N, Men A, Uppoor R, Mehta M, Wang Y.  J Pharm Sci. 2019 Apr;108(4):1598-1603. doi: 10.1016/j.xphs.2018.11.027.